Richard Silver PV

More documents

Recommendations

Info

So, Is Polycythemia Vera Curable?
Myeloproliferative Neoplasms (MPNs) The State of Affairs re. Mutations in 2012 Mutation <strong>PV</strong> (%) ET (%) MF (%) JAK2 V617F 95-99 50-70 40-50 JAK2 exon 12 Rare None None MPL exon 10 Rare 4 11 post- MPN AML (%) TET2 15 4-11 19 26 CBL Rare Rare 6 IDH 1.9 0.8 4.2 21.6 IKZF1 Rare Rare Rare 21 EZH2 3 None 13 ASXL1 exon 12
Page 1 and 2: On the “Curability” of Polycyth
Page 3 and 4: 15-2 CUMULATIVE SURVIVAL 1.0 0.8 0.
Page 5 and 6: Treatment • Worldwide, the majori
Page 7 and 8: On the Curability of Polycythemia V
Page 9 and 10: Pegylated IFNs • Peg-IFN α-2b: u
Page 11 and 12: On the Curability of Polycythemia V
Page 13 and 14: Percent (%) Progression-Free Surviv
Page 15 and 16: Molecular Changes with Peg-rIFNα
Page 17 and 18: PHLEBOTOMY REQUIREMENTS DURING THE
Page 19 and 20: Therapeutic Conundrum Is it prefera
Page 22 and 23: 2/11/2009: H&E sec.on (20X): increa
Page 24 and 25: 2/11/2009: 40X: Trichrome special s
Page 26 and 27: 7/27/2011: 20X, re.culin special st
Page 30 and 31: Role of Other Mutations 1. TET2 mut
Page 32 and 33: Is polycythemia vera curable with I
Page 35: Acknowledgement and Thanks to . . .
Page 39 and 40: Derived HCT (%) 55 50 45 40 35 30 D
Page 41 and 42: Spun HCT 55 50 45 40 35 30 Spun HCT
Page 43 and 44: RBC vs. Hgb Microcytic
Page 45 and 46: Outline of lecture 1) How is polycy
Page 47 and 48: Major criteria WHO criteria for PV
Page 49 and 50: “Those who cannot remember the pa
Page 51 and 52: An evaluation of 30 JAK2 V617F (+)
Page 53 and 54: N=4 N=9 N=0 N=0 N = 13
Page 55 and 56: Evaluation of Minor Criteria Minor
Page 57: Study Type of Interferon/ No. of Pt

Richard Silver PV

Create successful ePaper yourself

Delete template?

Save as template?